FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2484799355> ?p ?o ?g. }

• W2484799355 endingPage "56712" @default.
• W2484799355 startingPage "56699" @default.
• W2484799355 abstract "// Matthieu Corvaisier 1 , Marjolaine Bauzone 1 , François Corfiotti 1, 2 , Florence Renaud 1, 3 , Mehdi El Amrani 1, 2 , Didier Monté 4 , Stéphanie Truant 1, 2 , Emmanuelle Leteurtre 1, 3 , Pierre Formstecher 1 , Isabelle Van Seuningen 1 , Christian Gespach 5, * , Guillemette Huet 1, 3, * 1 University Lille, Inserm, CHU Lille, UMR-S1172-JPARC-Jean-Pierre Aubert Research Center, F-59000, Lille, France 2 Department of Digestive Surgery and Transplantation, CHRU Lille, F-59000, Lille, France 3 Center of Biology-Pathology, CHRU Lille, F-59000, Lille, France 4 UMR8576 CNRS-Université de Lille Nord de France, F-59658, Villeneuve d'Ascq, France 5 INSERM U938, “Molecular and Clinical Oncology”, Hôpital Saint-Antoine, University Pierre et Marie Curie, F-75012, Paris, France * These authors contributed equally to this work Correspondence to: Guillemette Huet, email: guillemette.huet@inserm.fr Keywords: c-Myc, CREB, stemness, liver metastases, prognosis Received: May 20, 2016      Accepted: July 13, 2016      Published: August 04, 2016 ABSTRACT Our aim was to decipher the role and clinical relevance of the YAP/TAZ transcriptional coactivators in the regulation of the proliferation/quiescence balance in human colon cancer cells (CCC) and survival after 5FU-based chemotherapy. The prognostic value of YAP/TAZ on tumor relapse and overall survival was assessed in a five-year follow-up study using specimens of liver metastases ( n = 70) from colon cancer patients. In 5FU-chemoresistant HT29-5F31 and -chemosensitive HCT116 and RKO CCC, a reversible G0 quiescent state mediated by Cyclin E1 down-regulation was induced by 5FU in 5F31 cells and recapitulated in CCC by either YAP/TAZ or Cyclin E1 siRNAs or the YAP inhibitor Verteporfin. Conversely, the constitutive active YAPdc-S127A mutant restricted cellular quiescence in 5FU-treated 5F31 cells and sustained high Cyclin E1 levels through CREB Ser-133 phosphorylation and activation. In colon cancer patients, high YAP/TAZ level in residual liver metastases correlated with the proliferation marker Ki-67 ( p < 0.0001), high level of the YAP target CTGF ( p = 0.01), shorter disease-free and overall survival ( p = 0.008 and 0.04, respectively). By multivariate analysis and Cox regression model, the YAP/TAZ level was an independent factor of overall (Hazard ratio [CI 95%] 2.06 (1.02–4.16) p = 0.045) and disease-free survival (Hazard ratio [CI 95%] 1.98 (1.01–3.86) p = 0.045). Thus, YAP/ TAZ pathways contribute to the proliferation/quiescence switch during 5FU treatment according to the concerted regulation of Cyclin E1 and CREB. These findings provide a rationale for therapeutic interventions targeting these transcriptional regulators in patients with residual chemoresistant liver metastases expressing high YAP/TAZ levels." @default.
• W2484799355 created "2016-08-23" @default.
• W2484799355 creator A5001459949 @default.
• W2484799355 creator A5008843589 @default.
• W2484799355 creator A5010603256 @default.
• W2484799355 creator A5010941913 @default.
• W2484799355 creator A5014125860 @default.
• W2484799355 creator A5030555009 @default.
• W2484799355 creator A5045830986 @default.
• W2484799355 creator A5052850973 @default.
• W2484799355 creator A5057376310 @default.
• W2484799355 creator A5065142060 @default.
• W2484799355 creator A5066196909 @default.
• W2484799355 creator A5066576409 @default.
• W2484799355 date "2016-08-04" @default.
• W2484799355 modified "2023-10-18" @default.
• W2484799355 title "Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse" @default.
• W2484799355 cites W184368635 @default.
• W2484799355 cites W1871742131 @default.
• W2484799355 cites W1966383348 @default.
• W2484799355 cites W1970068078 @default.
• W2484799355 cites W1982622947 @default.
• W2484799355 cites W1990624451 @default.
• W2484799355 cites W1991731514 @default.
• W2484799355 cites W1992294689 @default.
• W2484799355 cites W1998738134 @default.
• W2484799355 cites W2009421314 @default.
• W2484799355 cites W2009591068 @default.
• W2484799355 cites W2020131167 @default.
• W2484799355 cites W2027150010 @default.
• W2484799355 cites W2040430549 @default.
• W2484799355 cites W2040964625 @default.
• W2484799355 cites W2042619042 @default.
• W2484799355 cites W2049717739 @default.
• W2484799355 cites W2054428162 @default.
• W2484799355 cites W2064644124 @default.
• W2484799355 cites W2072624174 @default.
• W2484799355 cites W2074113171 @default.
• W2484799355 cites W2076306819 @default.
• W2484799355 cites W2079015343 @default.
• W2484799355 cites W2088359631 @default.
• W2484799355 cites W2095601153 @default.
• W2484799355 cites W2098692163 @default.
• W2484799355 cites W2099709490 @default.
• W2484799355 cites W2100641053 @default.
• W2484799355 cites W2108516575 @default.
• W2484799355 cites W2117344319 @default.
• W2484799355 cites W2118671972 @default.
• W2484799355 cites W2123511906 @default.
• W2484799355 cites W2126712555 @default.
• W2484799355 cites W2134066558 @default.
• W2484799355 cites W2134937820 @default.
• W2484799355 cites W2135726634 @default.
• W2484799355 cites W2140397999 @default.
• W2484799355 cites W2140582160 @default.
• W2484799355 cites W2142807621 @default.
• W2484799355 cites W2143076230 @default.
• W2484799355 cites W2146016283 @default.
• W2484799355 cites W2150163671 @default.
• W2484799355 cites W2150322923 @default.
• W2484799355 cites W2156718395 @default.
• W2484799355 cites W2159196011 @default.
• W2484799355 cites W2159376228 @default.
• W2484799355 cites W2166576553 @default.
• W2484799355 cites W2167978765 @default.
• W2484799355 cites W2169110374 @default.
• W2484799355 cites W2331089336 @default.
• W2484799355 cites W2341467683 @default.
• W2484799355 doi "https://doi.org/10.18632/oncotarget.11057" @default.
• W2484799355 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5302946" @default.
• W2484799355 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27527859" @default.
• W2484799355 hasPublicationYear "2016" @default.
• W2484799355 type Work @default.
• W2484799355 sameAs 2484799355 @default.
• W2484799355 citedByCount "33" @default.
• W2484799355 countsByYear W24847993552017 @default.
• W2484799355 countsByYear W24847993552018 @default.
• W2484799355 countsByYear W24847993552019 @default.
• W2484799355 countsByYear W24847993552020 @default.
• W2484799355 countsByYear W24847993552021 @default.
• W2484799355 countsByYear W24847993552022 @default.
• W2484799355 countsByYear W24847993552023 @default.
• W2484799355 crossrefType "journal-article" @default.
• W2484799355 hasAuthorship W2484799355A5001459949 @default.
• W2484799355 hasAuthorship W2484799355A5008843589 @default.
• W2484799355 hasAuthorship W2484799355A5010603256 @default.
• W2484799355 hasAuthorship W2484799355A5010941913 @default.
• W2484799355 hasAuthorship W2484799355A5014125860 @default.
• W2484799355 hasAuthorship W2484799355A5030555009 @default.
• W2484799355 hasAuthorship W2484799355A5045830986 @default.
• W2484799355 hasAuthorship W2484799355A5052850973 @default.
• W2484799355 hasAuthorship W2484799355A5057376310 @default.
• W2484799355 hasAuthorship W2484799355A5065142060 @default.
• W2484799355 hasAuthorship W2484799355A5066196909 @default.
• W2484799355 hasAuthorship W2484799355A5066576409 @default.
• W2484799355 hasBestOaLocation W24847993551 @default.
• W2484799355 hasConcept C121608353 @default.
• W2484799355 hasConcept C126322002 @default.

• next